CURRICULUM VITAE

CURRICULUM VITAE
DOMINIK WOLF
Education
July 92
Okt. 92 – Jan 94
May 94 – Oct. 2000
Abitur, Goldberg-Gymnasium Sindelfingen
Civil Service at the Institute for Radiology, University
Hospital Regenburg
Medical Training at the University of ErlangenNürnberg
MD Thesis:
Finished January 2002 with distinction („summa cum laude“), supported by the DFG
(Graduiertenkolleg).
Clinical Education:
Since February 2001
Since August 2006
Since March 2008
April 2007
Since April 2008
Since December 2009
From October 2011
Residency at the Department of Hematology and
Oncology, Medical University Innsbruck, Austria
(Chair: Prof. Dr. G. Gastl)
Head of the Laboratory of Tumorimmunology at the
Department of Hematology and Oncology, Medical
University Innsbruck , Austria
Program Director for Chronic Myeloproliferative
Diseases at the Department of Hematology and
Oncology, Medical University Innsbruck , Austria
Board certification Internal Medicine
Privatdozent/PD (“venia legendi”) for Internal
Medicine, Medical University Innsbruck, Austria
Specialist in Hematology/Oncology
W2 Professorship for Tumorimmunology, University
of Bonn, Germany
Awards:
MD-thesis poster-award of the University of Erlangen-Nürnberg 2002
MD-thesis award by the Staedtler-Foundation 2002
Annual Award of the Austrian Society of Nephrology 2005
Schönmann Krebsforschungspreis 2007
Sanofi-Aventis Preis 2009
Ad hoc reviewing:
The Lancet
Leukemia
Journal of the American Society of Nephrology (JASN)
Clin Cancer Res
Exp Rev Haematology
Int J Cancer
Br J Haematol
J Leuk Biol
Br J Cancer
Swiss National Science Foundation
Forschungsfond der Österreichischen Nationalbank
Memberships:
Austrian Society of Hematology and Oncology (OEGHO) Scientific Board
Member
German Society of Hematology and Oncology (DGHO)
European Society of Hematology (EHA)
Patents:
Co-applicant:
METHOD
FOR
INCREASING
IMMUNOREACTIVITY
(WO/2009/073905)
Co-applicant: METHOD FOR DETERMNING CBL-B EXPRESSION
(WO/2010/119061 A1)
Clinical Trials:
PI of various academic and industry-sponsored Phase I to Phase III clinical trials.
Varia:
Guest Editor Current Cancer Drug Targets
Funding (non-industrial):
FWF
FFG (Oncotyrol)
OEGHO
SFB 021 “Young investigator” (Tiroler Zukunftstiftung)
MFF Tirol
Tiroler Krebshilfe